Treatment of relapse of breast cancer after adjuvant systemic therapy--review and guidelines for future research (Q40732551)

23 September 2017

1 reference

title

Treatment of relapse of breast cancer after adjuvant systemic therapy--review and guidelines for future research (English)

1 reference

23 September 2017

5

Lønning PE

1 reference

23 September 2017

Rubens RD

1

1 reference

23 September 2017

Bajetta E

2

1 reference

23 September 2017

Bonneterre J

3

1 reference

23 September 2017

Klijn JG

4

1 reference

23 September 2017

Paridaens R

6

1 reference

23 September 2017

publication date

1 January 1994

1 reference

European Journal of Cancer

23 September 2017

published in

1 reference

23 September 2017

volume

30A

1 reference

23 September 2017

issue

1

1 reference

23 September 2017

page(s)

106-111

1 reference

Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

The influence of adjuvant chemotherapy on outcome after relapse for patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer. The French Epirubicin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Effect of adjuvant systemic therapy on response to treatment after relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Adjuvant systemic treatment and the pattern of recurrences in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

P-glycoprotein expression in treated and untreated human breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Clinical Relevance of Immunohistochemical Detection of Multidrug Resistance P-Glycoprotein in Breast Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Adriamycin effects on hydroperoxide metabolism and growth of human breast tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Transforming growth factor beta 1 is implicated in the failure of tamoxifen therapy in human breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Treatment of breast carcinoma with aminoglutethimide.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Relationship between proliferative activity and estrogen receptors in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Correlation between steroid hormone receptors and prognostic factors in human breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

The prognostic value of estrogen receptor determinations in patients with primary breast cancer: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Ploidy Level of Human Breast Carcinoma Relation to Histopathologic Features and Hormone Receptor Content

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Cell biological factors associated with the response of breast cancer to systemic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

The value of progesterone receptor assays in the management of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Clinical pharmacokinetics of endocrine agents used in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Clinical trials of agents that reverse multidrug-resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Stereochemistry of Intercalation: Interaction of Daunomycin with DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

The anticancer agent adriamycin can be actively cytotoxic without entering cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

The effects of therapy on estrogen receptors in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Up-regulation of estrogen receptor by tamoxifen in human breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss Group for Clinical Cancer Research

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized study of CMF vs CMF plus tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

Cisplatin as first-line therapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980029-2

7 January 2021

10.1016/S0959-8049(05)80029-2

Identifiers

DOI

1 reference

23 September 2017

1 reference